Cochrane Evidence Synthesis and Methods ►

Thyroid dysfunction during treatment with systemic antineoplastic therapy for childhood cancer

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To gain insight into the occurrence of and risk factors for aberrant thyroid function parameters (i.e. TSH, free thyroxine (FT4)) as expression of hypothyroidism, hyperthyroidism, or NTI during cancer treatment in children treated with systemic antineoplastic therapy.

This is a protocol.

Published:

14 December 2020

Authors:

Lebbink CA, Lentjes EGWM, Tissing WJE, van den Heuvel-Eibrink MM, van Santen HM, van Dalen EC

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Lebbink CA, Lentjes EGWM, Tissing WJE, van den Heuvel-Eibrink MM, van Santen HM, van Dalen EC. Thyroid dysfunction during treatment with systemic antineoplastic therapy for childhood cancer (Protocol). Cochrane Database of Systematic Reviews 2020, Issue 12. Art. No.: CD013805. DOI: 10.1002/14651858.CD013805.